ICUIHIGH SIGNALREGULATORY10-K

ICUI received a new FDA warning letter in 2025 regarding critical infusion pump products while simultaneously achieving a dramatic turnaround from a $117.7M net loss to profitability.

The new FDA warning letter concerning modifications to key infusion pump products represents a significant regulatory setback that could restrict commercial activity and sales of core products. However, this regulatory risk is counterbalanced by the company's remarkable financial turnaround, suggesting underlying operational improvements despite the compliance challenges.

Comparing 2026-02-19 vs 2025-02-27View on EDGAR →
FINANCIAL ANALYSIS

ICUI demonstrated a dramatic financial recovery, swinging from a $117.7M net loss to $732K profit, representing a complete turnaround in profitability. However, the company's cash position declined significantly by 62.2% to $208.8M, while operating cash flow dropped 11.9% to $179.8M and current assets fell 17.4%, suggesting the turnaround may have come at the cost of liquidity and working capital optimization. The overall financial picture shows improved earnings but weaker cash generation and balance sheet strength.

FINANCIAL STATEMENT CHANGES
Net Income
P&L
+100.6%
-$117.7M→$732K

Net income grew 100.6% — bottom-line growth signals improving overall business health.

Cash & Equivalents
Balance Sheet
-62.2%
$552.8M→$208.8M

Cash declined 62.2% — significant cash burn or deployment; verify adequacy of remaining liquidity runway.

Share Buybacks
Cash Flow
-26.9%
$12.0M→$8.8M

Buyback activity reduced 26.9% — capital being redeployed elsewhere or cash conservation underway.

Current Assets
Balance Sheet
-17.4%
$1.4B→$1.2B

Current assets declined 17.4% — monitor working capital adequacy and short-term liquidity.

Operating Cash Flow
Cash Flow
-11.9%
$204.0M→$179.8M

Operating cash flow softened — monitor whether temporary working capital timing or structural deterioration.

Current Liabilities
Balance Sheet
-10.3%
$556.2M→$498.9M

Current liabilities reduced — improved short-term financial position and working capital health.

LANGUAGE CHANGES
NEW — 2026-02-19
PRIOR — 2025-02-27
ADDED
trade, tax or other policies that restrict imports or increase import tariffs for certain countries, particularly Mexico and Costa Rica; continuing pressures to reduce healthcare costs and inadequate coverage and reimbursement; our ability to comply with applicable laws, rules and regulations, including, without limitation, matters raised in a warning letter issued by the FDA in 2025, regarding modifications to our cleared MedFusion Model 4000 Syringe Infusion Pump and CADD Solis VIP Ambulatory Infusion Pump that could impact our continued commercial activity.
Principal risks and uncertainties include: We derive a significant portion of our revenues from non-U.S.
We are therefore subject to risks of doing business in other countries, including those related to tariffs, retaliatory counter measures and further escalation of trade tensions.
Continuing pressures to reduce healthcare costs and inadequate coverage and reimbursement may adversely affect our prices and volume.
ICU's product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, sharps safety products, and sterile IV solutions offered on behalf of our joint venture; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products.
+7 more — sign up free →
REMOVED
trade, tax or other policies that restrict imports or increase import tariffs for certain countries, particularly Mexico, will escalate trade wars and will have a material adverse effect on our results of operations.
Continuing pressures to reduce healthcare costs and inadequate coverage and reimbursement may adversely affect our prices.
In particular, if we are unable to resolve or close-out the Warning Letter dated October 1, 2021, received by Smiths Medical ASD, Inc.
from the Minneapolis, Minnesota Facility following a February to March 2021 inspection, we could suffer significant sanctions which may impact our ability to sell products globally.
ICU's product portfolio includes ambulatory, syringe, and large volume IV pumps and safety software; dedicated and non-dedicated IV sets, needlefree IV connectors, peripheral IV catheters, sharps safety products, and sterile IV solutions; closed system transfer devices and pharmacy compounding systems; as well as a range of respiratory, anesthesia, patient monitoring, and temperature management products.
+7 more — sign up free →
MORE REGULATORY SIGNALS
BCHTHIGHBCHT has added extensive PFAS chemical definitions to their 10-K while removing ...
2026-03-31
OMERHIGHOMER achieved FDA approval for YARTEMLEA in December 2025, transforming from a c...
2026-03-31
UNCYHIGHThe FDA issued a Complete Response Letter (CRL) in June 2025 rejecting UNCY's dr...
2026-03-30
NVNOHIGHNVNO received a not-approvable letter from the FDA for its lead product VenoValv...
2026-03-26
ANALYZE ANY FILING FREE

See what changed in your portfolio's filings

500+ US-listed companies analyzed. Language delta, financial analysis, instant signal scoring.

Try Tracenotes free →